In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

European Life Sciences Start-Ups Maintain Early Investor Allure

Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.

Europe Financing BioPharmaceutical

GE Healthcare’s New Value Proposition: The Strategic Language Of Software

For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.

BioPharmaceutical Business Strategies Leadership

Value-Based Health Care: US Lags In The Global Shift To Outcomes

The adoption of value-based health care concepts among US providers is happening, albeit slowly. In what is an unusual reversal of pioneering health care concepts, the pace is being set elsewhere – in Europe – rather than in the US, even if the direction of travel has been firmly established. Boston Consulting Group experts give In Vivo an interim update on the progress and outlook for VBHC.

Market Access Medical Device Business Strategies

In Vivo's Deals Of The Month, February 2018

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
Deals Market Intelligence BioPharmaceutical

2018 Outlook

Insights from In Vivo on what to expect in the coming year

Recent Tweets from In Vivo

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio

Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.

BioPharmaceutical Growth

Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap

Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.

BioPharmaceutical Research and Development Strategies

True To Its Word, LivaNova Sheds CRM – To MicroPort

One of the cleanest and swiftest M&A deals of recent months was the twinning of LivaNova's CRM business with MicroPort's enhanced ambitions in a $10 billion global market. What now for these two medtech innovators?

Business Strategies M & A

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can

Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.

Digital Health Innovation

Cross-Country Collaboration: With Schrodinger Technology at the Core

Schrodinger pact with MaRS Innovation aims to tackle anti-fungal resistance.
Digital Health Innovation

Data And The Digital Horizon: Perspective From The Agency C-suite

While digital health applications represent a major opportunity for biopharma, acting on the premise – and realizing its promise – depends on quantum-level shifts in organizational design and cultural resilience to disruptive change.  In an In Vivo interview, Omnicom Health Group’s SVP for Data Solutions Christina Kim says industry progress toward a digitized future varies, but the necessity to act is clear. 

Digital Health Business Strategies

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, March 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

US Medtechs Won't Rest On Laurels After Excise Tax Victory

In the polarized environment of Washington DC, the US medtech industry was becoming increasingly concerned as 2017 turned to 2018 that the medical device sales tax would be reinstated after a two-year suspension. AdvaMed chairman Nadim Yared tells In Vivo about the efforts and lobbying that got Congressmen onside just in time – but the battle doesn’t stop there.

Leadership Medical Device

Execs On The Move, February 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat

The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.


Market Access Digital Health

Doubling Pharma Value With Data Science

A once-in-a-generation opportunity has opened to digitally redesign a core part of the biopharma business. Capturing the opportunity requires vision and leadership; it’s not about the technology.

Digital Health Business Strategies

The Tailor Will See You Now – J&J's EMEA VP Explains Total Care Partnership For Hospital Systems

Johnson & Johnson's global CareAdvantage system, a tool to help hospital systems deliver quality care efficiently and affordably, was launched in spring 2017. Almost a year into the initiative, Hugo Breda, the group’s EMEA vice president, explains the role that J&J plays as it brings its unique care provision concept to clients.

Business Strategies Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Digital Deals And Life Sciences: Avoiding Death By A Thousand Pilots

EY executive survey yields insights into how digital technology is helping drive biopharma deal strategy and aiding companies to meet competitive challenges.

Digital Health Deals

Deals In Depth: January 2018

In a $1.2 billion deal, Takeda and Denali are jointly developing and commercializing Alzheimer's antibodies. Celgene did two big oncology bolt-on acquisitions, buying Juno and Impact. Chinese company BeiGene completed a $758 million follow-on public offering.
Deals Market Intelligence

Deals Shaping The Medical Industry, March 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2018.  
Deals BioPharmaceutical